Your browser doesn't support javascript.
Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from PREPARE-IBD
Gut ; 70(Suppl 4):A23, 2021.
Article in English | ProQuest Central | ID: covidwho-1506274
ABSTRACT
ATU-3 Frigure 1ConclusionsOur data provide reassurance for the continued evidence-based use of corticosteroids, immunomodulators and biologic therapies in IBD during the ongoing COVID-19 pandemic, and is consistent with an as yet unexplained association between mesalazine use and severe COVID-19 outcomes.

Full text: Available Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Language: English Journal: Gut Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Language: English Journal: Gut Year: 2021 Document Type: Article